|Bid||1.5100 x 900|
|Ask||1.5300 x 800|
|Day's Range||1.4720 - 1.5700|
|52 Week Range||1.0300 - 7.9700|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply...
The Dublin-based company said it had a loss of 35 cents per share. The specialty pharmaceutical company posted revenue of $16.4 million in the period. The company's shares closed at $1.20. A year ago, ...
Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
The Dublin-based company said it had a loss of $1.72 per share. The specialty pharmaceutical company posted revenue of $20.9 million in the period. For the year, the company reported a loss of $95.3 million, ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
The Dublin-based company said it had a loss of 43 cents per share. The specialty pharmaceutical company posted revenue of $19.8 million in the period. Avadel expects full-year revenue in the range of $90 ...
The firm founded Charles Brandes (Trades, Portfolio), Brandes Investment Partners, on Thursday announced that it expanded its position in Avadel Pharmaceuticals Plc (AVDL) to 13.5% of the company, enlarging its exposure to health care, the second-largest sector represented in its portfolio. Warning! GuruFocus has detected 8 Warning Signs with PFE. The value investing firm has been building its stake in Avadel as the company's stock price has declined.
On a per-share basis, the Dublin-based company said it had a loss of 9 cents. The specialty pharmaceutical company posted revenue of $29.2 million in the period. Avadel shares have declined 27 percent ...
This analysis is intended to introduce important early concepts to people who are starting to invest and looking to gauge the potential return on investment in Avadel Pharmaceuticals plc (NASDAQ:AVDL).Read More...